Systems and methods for treating inflammatory and proliferative diseases,
and wounds, using as a pharmacon a UCP and/or Fas antibody or other
inhibitor, or combination thereof, and a therapeutically acceptable
amount of a fatty acid metabolism inhibitor and/or a therapeutically
acceptable amount of a glucose metabolism inhibitor, optionally in
combination with one or more chemotherpeutic agents. In preferred
embodiments, the invention combines an antibody against UCP and/or Fas
antigen with an oxirane carboxylic acid, represented by etomoxir, and/or
with a 2-deoxyglucose compound, represented by 2-deoxy-D-glucose. The
systems and methods of the invention can be used to treat drug-resistant
or multi-drug resistant cancers.